<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04493671</url>
  </required_header>
  <id_info>
    <org_study_id>TBAJ-876-CL-001</org_study_id>
    <nct_id>NCT04493671</nct_id>
  </id_info>
  <brief_title>Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults</brief_title>
  <official_title>A Phase 1, Partially Blind, Placebo Controlled, Randomized, Combined Single Ascending Dose With a Food Effect Cohort (Part 1) and Multiple Ascending Dose Study (Part 2) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBAJ-876 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Alliance for TB Drug Development</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Alliance for TB Drug Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Partially Blind, Placebo Controlled, Randomized, Combined Single Ascending Dose&#xD;
      with a Food Effect Cohort (Part 1) and Multiple Ascending Dose Study (Part 2) Study to&#xD;
      Evaluate the Safety, Tolerability, and Pharmacokinetics of TBAJ-876 in Healthy Adult Subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a two-part, partially blinded, placebo controlled, combined single ascending&#xD;
      dose (SAD) with food-effect and multiple ascending dose (MAD) study conducted in one study&#xD;
      center in the United States.&#xD;
&#xD;
      Safety will be assessed throughout the study for all subjects. Safety assessments will&#xD;
      include physical examinations, vital signs, serial ECGs, cardiac monitoring, adverse events&#xD;
      (AEs), and clinical laboratory tests (including hematology, serum chemistry, coagulation, and&#xD;
      urinalysis).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 8, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical examination [Safety and Tolerability]</measure>
    <time_frame>Days -1</time_frame>
    <description>Safety assessments will include physical examination which will comprise measuring height in cm, weight in kg, and presence of heart murmur.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs [Safety and Tolerability]</measure>
    <time_frame>Days -1 - Day 60</time_frame>
    <description>Vital signs (blood pressure, pulse rate, temperature, respiration rate, and pulse oximetry) will be measured within 90 minutes prior to dosing and within 15 minutes of the defined time points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead safety ECGs [Safety and Tolerability]</measure>
    <time_frame>Days -1 - Day 28</time_frame>
    <description>Continuous 12-lead ECGs (Holter) will be recorded for 1 hours prior to dose and continue for at least 24 hours post dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Coagulation tests [Safety and Tolerability]</measure>
    <time_frame>Days -1 - Day 28</time_frame>
    <description>Coagulation Tests is for activated partial thromboplastin time (aPTT2), Prothrombin time (PT2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine pregnancy test (females only) [Safety and Tolerability]</measure>
    <time_frame>Day 28</time_frame>
    <description>Female subjects will have a urine pregnancy test done at the end-of-study Day 60 or early withdrawal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FSH test (Post-menopausal females) [Safety and Tolerability]</measure>
    <time_frame>Day -28 - Day -2</time_frame>
    <description>Females claiming postmenopausal status will have blood collected to measure FSH levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK blood collection [Safety and Tolerability]</measure>
    <time_frame>Day 1 - Day 28</time_frame>
    <description>PK samples to be collected at pre-dose and post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead safety ECGs [Safety and Tolerability]</measure>
    <time_frame>Day 1 - Day 60</time_frame>
    <description>ECGs will be performed pre-dose and post-dose at various time points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCExtrap [Pharmacokinetic Analysis]</measure>
    <time_frame>Days 1 - 28</time_frame>
    <description>PK parameters will be calculated from plasma concentrations of TBAJ-876 TBAJ-876, M2, and M3. AUCExtrap the percentage of extrapolated AUC to AUCinf based on extrapolation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf [Pharmacokinetic Analysis]</measure>
    <time_frame>Days 1 - 28</time_frame>
    <description>PK parameters will be calculated from plasma concentrations of TBAJ-876 TBAJ-876, M2, and M3. AUCinf is area under the concentration-time curve from time-zero extrapolated to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast [Pharmacokinetic Analysis]</measure>
    <time_frame>Days 1 - 28</time_frame>
    <description>PK parameters will be calculated from plasma concentrations of TBAJ-876 TBAJ-876, M2, and M3. AUClast area under the concentration-time curve from time-zero to the time of the last quantifiable concentration; calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau [Pharmacokinetic Analysis]</measure>
    <time_frame>Days 1 - 28</time_frame>
    <description>PK parameters will be calculated from plasma concentrations of TBAJ-876 TBAJ-876, M2, and M3. AUCtau is area under the concentration-time curve during the dosing interval; calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cavg [Pharmacokinetic Analysis]</measure>
    <time_frame>Days 1 - 28</time_frame>
    <description>PK parameters will be calculated from plasma concentrations of TBAJ-876 TBAJ-876, M2, and M3. Cavg is average concentration during the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clast [Pharmacokinetic Analysis]</measure>
    <time_frame>Days 1 - 28</time_frame>
    <description>PK parameters will be calculated from plasma concentrations of TBAJ-876 TBAJ-876, M2, and M3. Clast is the last quantifiable concentration determined directly from individual concentration-time data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F [Pharmacokinetic Analysis]</measure>
    <time_frame>Days 1 - 28</time_frame>
    <description>PK parameters will be calculated from plasma concentrations of TBAJ-876 TBAJ-876, M2, and M3. CL/F is apparent total clearance after single administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLss/F [Pharmacokinetic Analysis]</measure>
    <time_frame>Days 1 - 28</time_frame>
    <description>PK parameters will be calculated from plasma concentrations of TBAJ-876 TBAJ-876, M2, and M3. CLss/F is apparent total clearance after multiple administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax [Pharmacokinetic Analysis]</measure>
    <time_frame>Days 1 - 28</time_frame>
    <description>PK parameters will be calculated from plasma concentrations of TBAJ-876 TBAJ-876, M2, and M3. Cmax is maximum concentration, determined directly from individual concentration-time data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RAUC [Pharmacokinetic Analysis]</measure>
    <time_frame>Days 1 - 28</time_frame>
    <description>PK parameters will be calculated from plasma concentrations of TBAJ-876 TBAJ-876, M2, and M3. RAUC is accumulation factor during multiple dosing, based on AUCtau.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RCmax [Pharmacokinetic Analysis]</measure>
    <time_frame>Days 1 - 28</time_frame>
    <description>PK parameters will be calculated from plasma concentrations of TBAJ-876 TBAJ-876, M2, and M3. RCmax is accumulation factor during multiple dosing, based on Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tlast [Pharmacokinetic Analysis]</measure>
    <time_frame>Days 1 - 28</time_frame>
    <description>PK parameters will be calculated from plasma concentrations of TBAJ-876 TBAJ-876, M2, and M3. Tlast is time of the last quantifiable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax [Pharmacokinetic Analysis]</measure>
    <time_frame>Days 1 - 28</time_frame>
    <description>PK parameters will be calculated from plasma concentrations of TBAJ-876 TBAJ-876, M2, and M3. Tmax is time of the maximum concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 [Pharmacokinetic Analysis]</measure>
    <time_frame>Days 1 - 28</time_frame>
    <description>PK parameters will be calculated from plasma concentrations of TBAJ-876 TBAJ-876, M2, and M3. T1/2 is the observed terminal half-life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F [Pharmacokinetic Analysis]</measure>
    <time_frame>Days 1 - 28</time_frame>
    <description>PK parameters will be calculated from plasma concentrations of TBAJ-876 TBAJ-876, M2, and M3. Vz/F is apparent volume of distribution in the terminal phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz [Pharmacokinetic Analysis]</measure>
    <time_frame>Days 1 - 28</time_frame>
    <description>PK parameters will be calculated from plasma concentrations of TBAJ-876 TBAJ-876, M2, and M3. λz is the observed terminal rate constant; estimated by linear regression through at least 3 data points in the terminal phase of the log concentration-time profile.</description>
  </secondary_outcome>
  <number_of_arms>20</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Pulmonary Disease</condition>
  <condition>Tuberculosis, Pulmonary</condition>
  <condition>Tuberculosis</condition>
  <condition>Multi Drug Resistant Tuberculosis</condition>
  <condition>Drug Sensitive Tuberculosis</condition>
  <condition>Drug-resistant Tuberculosis</condition>
  <condition>Mycobacterium Tuberculosis Infection</condition>
  <arm_group>
    <arm_group_label>SAD (Part 1): Cohort 1, TBAJ-876 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In cohort 1 with 8 subjects, n= 6 will receive TBAJ-876 10mg under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD (Part 1): Cohort 1, placebo for TBAJ-876 10mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In cohort 1 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 10mg under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD (Part 1): Cohort 2, TBAJ-876 25mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In cohort 2 with 8 subjects, n= 6 will receive TBAJ-876 25mg under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD (Part 1): Cohort 2, Placebo for TBAJ-876 25mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In cohort 2 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 25mg under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD (Part 1): Cohort 3, TBAJ-876 50mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In cohort 3 with 8 subjects, n= 6 will receive TBAJ-876 50mg under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD (Part 1): Cohort 3, Placebo for TBAJ-876 50mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In cohort 3 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 50mg under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD (Part 1): Cohort 4, TBAJ-876 100mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In cohort 4 with 8 subjects, n= 6 will receive TBAJ-876 100mg under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD (Part 1): Cohort 4, Placebo for TBAJ-876 100mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In cohort 4 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 100mg under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD (Part 1): Cohort 5, TBAJ-876 200mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In cohort 5 with 8 subjects, n= 6 will receive TBAJ-876 200mg under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD (Part 1): Cohort 5, Placebo for TBAJ-876 200mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In cohort 5 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 200mg under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD (Part 1): Cohort 6, TBAJ-876 400mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In cohort 6 with 8 subjects, n= 6 will receive TBAJ-876 400mg under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD (Part 1): Cohort 6, Placebo TBAJ-876 400mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In cohort 6 with 8 subjects, n= 2 will receive matching placebo for TBAJ-876 400mg under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD (Part 1): Food effect Cohort, TBAJ-876</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In food-effect cohort with 10 subjects, n=8 will return after plasma concentrations are expected to be below LLQ, for at least 7 days to receive the chosen dose of TBAJ-876 under fed conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD (Part 1): Food effect Cohort, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In food-effect cohort with 10 subjects, n=2 will return after plasma concentrations are expected to be below LLQ, for at least 7 days to receive matching placebo for the chosen dose of TBAJ-876 under fed conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD (Part 2): Cohort 1, TBAJ-876 Dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In cohort 1 with 12 subjects, n=9 is expected to receive TBAJ-876 for 28 days with corresponding PK and safety measurements.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD (Part 2): Cohort 1, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In cohort 1 with 12 subjects, n=3 is expected to receive the matching placebo for TBAJ-876 for 28 days with corresponding PK and safety measurements.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD (Part 2): Cohort 2, TBAJ-876 Dose 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In cohort 2 with 12 subjects, n=9 is expected to receive TBAJ-876 for 28 days with corresponding PK and safety measurements.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD (Part 2): Cohort 2, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In cohort 2 with 12 subjects, n=3 is expected to receive matching placebo for TBAJ-876 for 28 days with corresponding PK and safety measurements.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD (Part 2): Cohort 3, TBAJ-876 Dose 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In cohort 3 with 12 subjects, n=9 is expected to receive TBAJ-876 for 28 days with corresponding PK and safety measurements</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD (Part 2): Cohort 3, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In cohort 3 with 12 subjects, n=3 is expected to receive matching placebo for TBAJ-876 for 28 days with corresponding PK and safety measurements.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBAJ-876 10mg</intervention_name>
    <description>TBAJ-876 10mg tablets, oral suspension, orally administered</description>
    <arm_group_label>SAD (Part 1): Cohort 1, TBAJ-876 10mg</arm_group_label>
    <other_name>TBAJ-876 tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBAJ-876 25mg</intervention_name>
    <description>TBAJ-876 25mg tablets,oral suspension, orally administered</description>
    <arm_group_label>SAD (Part 1): Cohort 2, TBAJ-876 25mg</arm_group_label>
    <other_name>TBAJ-876 tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBAJ-876 50mg</intervention_name>
    <description>TBAJ-876 50mg tablets,oral suspension, orally administered</description>
    <arm_group_label>SAD (Part 1): Cohort 3, TBAJ-876 50mg</arm_group_label>
    <other_name>TBAJ-876 tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBAJ-876 100mg</intervention_name>
    <description>TBAJ-876 100mg tablets, oral suspension, orally administered</description>
    <arm_group_label>SAD (Part 1): Cohort 4, TBAJ-876 100mg</arm_group_label>
    <other_name>TBAJ-876 tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBAJ-876 200mg</intervention_name>
    <description>TBAJ-876 200mg tablets, oral suspension, orally administered</description>
    <arm_group_label>SAD (Part 1): Cohort 5, TBAJ-876 200mg</arm_group_label>
    <other_name>TBAJ-876 tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBAJ-876 400mg</intervention_name>
    <description>TBAJ-876 400mg tablets, oral suspension, orally administered</description>
    <arm_group_label>SAD (Part 1): Cohort 6, TBAJ-876 400mg</arm_group_label>
    <other_name>TBAJ-876 tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBAJ-876 Dose XXXmg for Food cohort</intervention_name>
    <description>Based on exposure levels from initial cohorts, a dose will be chosen for the food-effect cohort.</description>
    <arm_group_label>SAD (Part 1): Food effect Cohort, TBAJ-876</arm_group_label>
    <other_name>TBAJ-876 tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBAJ-876 XXXmg for Part 2</intervention_name>
    <description>Part 2, Multiple ascending dose (MAD) cohorts doses to be determined.</description>
    <arm_group_label>MAD (Part 2): Cohort 1, TBAJ-876 Dose 1</arm_group_label>
    <arm_group_label>MAD (Part 2): Cohort 2, TBAJ-876 Dose 2</arm_group_label>
    <arm_group_label>MAD (Part 2): Cohort 3, TBAJ-876 Dose 3</arm_group_label>
    <other_name>TBAJ-876 tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo for TBAJ-876 tablet</intervention_name>
    <description>Matching Placebo for TBAJ-876 tablets, oral suspension, orally administered</description>
    <arm_group_label>MAD (Part 2): Cohort 1, Placebo</arm_group_label>
    <arm_group_label>MAD (Part 2): Cohort 2, Placebo</arm_group_label>
    <arm_group_label>MAD (Part 2): Cohort 3, Placebo</arm_group_label>
    <arm_group_label>SAD (Part 1): Cohort 1, placebo for TBAJ-876 10mg</arm_group_label>
    <arm_group_label>SAD (Part 1): Cohort 2, Placebo for TBAJ-876 25mg</arm_group_label>
    <arm_group_label>SAD (Part 1): Cohort 3, Placebo for TBAJ-876 50mg</arm_group_label>
    <arm_group_label>SAD (Part 1): Cohort 4, Placebo for TBAJ-876 100mg</arm_group_label>
    <arm_group_label>SAD (Part 1): Cohort 5, Placebo for TBAJ-876 200mg</arm_group_label>
    <arm_group_label>SAD (Part 1): Cohort 6, Placebo TBAJ-876 400mg</arm_group_label>
    <arm_group_label>SAD (Part 1): Food effect Cohort, Placebo</arm_group_label>
    <other_name>TBAJ-876 placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All volunteers must satisfy the following criteria to be considered for study&#xD;
        participation:&#xD;
&#xD;
          1. Understands study procedures and voluntarily provides written informed consent prior&#xD;
             to the start of any study-specific procedures.&#xD;
&#xD;
          2. Is a healthy adult male or female, 19 to 50 years of age (inclusive) at the time of&#xD;
             screening.&#xD;
&#xD;
          3. Has a body mass index (BMI) ≥18.5 and ≤32.0 (kg/m2) and a body weight of no less than&#xD;
             50.0 kg.&#xD;
&#xD;
          4. Is medically healthy with no clinically significant screening results (e.g.,&#xD;
             laboratory profiles normal or up to Grade 1 per DMID Toxicity Tables), as deemed by&#xD;
             the Investigator. Note: Lab results within the testing facility's normal range will&#xD;
             not be considered AEs when referenced to the DMID assessment/grading scale. If&#xD;
             exclusionary lab criteria are met, values may be confirmed by repeat evaluation.&#xD;
&#xD;
          5. Has not used tobacco- or nicotine-containing products (including smoking cessation&#xD;
             products), for a minimum of 6 months before dosing.&#xD;
&#xD;
          6. If female of non-childbearing potential, she has undergone one of the following&#xD;
             sterilization procedures at least 6 months before dosing:&#xD;
&#xD;
               -  Hysteroscopic sterilization;&#xD;
&#xD;
               -  Bilateral tubal ligation or bilateral salpingectomy;&#xD;
&#xD;
               -  Hysterectomy; or&#xD;
&#xD;
               -  Bilateral oophorectomy;&#xD;
&#xD;
               -  Or is postmenopausal with amenorrhea for at least 1 year before the first dose&#xD;
                  with serum FSH levels consistent with postmenopausal status (i.e., greater than&#xD;
                  40 mIU/mL) at screening.&#xD;
&#xD;
          7. If female of childbearing potential, must be using effective birth control methods, as&#xD;
             defined below and is willing to continue practicing birth control methods and not&#xD;
             planning to conceive throughout treatment and for 12 weeks (male participants) or 6&#xD;
             weeks (female participants) after the last dose of trial medication. The following are&#xD;
             allowed birth control methods for this study:&#xD;
&#xD;
               -  Double barrier method (e.g., diaphragm with spermicide; condoms with spermicide);&#xD;
&#xD;
               -  Intrauterine device (IUD);&#xD;
&#xD;
               -  Abstinence (and must agree to use a double barrier method if they become sexually&#xD;
                  active during the study);&#xD;
&#xD;
               -  Vasectomized partner (at least 6 months before dosing);&#xD;
&#xD;
               -  Non-surgical permanent sterilization (e.g., Essure® procedure) at least 3 months&#xD;
                  before dosing;&#xD;
&#xD;
               -  Implanted or intrauterine hormonal contraceptives in use for at least 6&#xD;
                  consecutive months before study dosing; and/or&#xD;
&#xD;
          8. If a non-vasectomized male (or male vasectomized less than 120 days prior to study&#xD;
             start) he must agree to the following during study participation and for 90 days after&#xD;
             the last administration of study drug:&#xD;
&#xD;
               -  Use a condom with spermicide while engaging in sexual activity or be sexually&#xD;
                  abstinent; and&#xD;
&#xD;
               -  Not donate sperm during this time. In the event the sexual partner is surgically&#xD;
                  sterile or postmenopausal, use of a condom with spermicide is not necessary. None&#xD;
                  of the birth control restrictions listed above are required for vasectomized&#xD;
                  males whose procedure was performed more than 120 days before study start.&#xD;
&#xD;
          9. Is willing to answer inclusion and exclusion criteria questionnaire at check-in.&#xD;
&#xD;
         10. Is able to comply with the protocol and the assessments therein, including all&#xD;
             restrictions.&#xD;
&#xD;
         11. Is willing and able to remain in the study unit for the entire duration of the&#xD;
             assigned confinement period and return for outpatient visits.&#xD;
&#xD;
         12. If assigned to receive study drug under fed conditions, is willing and able to consume&#xD;
             the entire high-calorie, high-fat breakfast meal in the timeframe required.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Volunteers will be excluded from study participation for any of the following:&#xD;
&#xD;
          1. History or presence of clinically significant cardiovascular (heart murmur),&#xD;
             pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic,&#xD;
             dermatologic, neurologic, psychiatric disease or any other condition that, in the&#xD;
             opinion of the Investigator, would jeopardize the safety of the subject or the&#xD;
             validity of the study results.&#xD;
&#xD;
          2. Any presence of musculoskeletal toxicity (severe tenderness with marked impairment of&#xD;
             activity, or frank necrosis).&#xD;
&#xD;
          3. Surgery within the past 90 days prior to dosing as determined by the Investigator to&#xD;
             be clinically relevant.&#xD;
&#xD;
          4. History or presence of alcoholism or drug abuse within the past 2 years as determined&#xD;
             by the Investigator to be clinically relevant.&#xD;
&#xD;
          5. Participation in another clinical trial within 30 days prior to dosing.&#xD;
&#xD;
          6. Female subjects who are pregnant or lactating.&#xD;
&#xD;
          7. Positive result on a urine drug/alcohol screen at screening or check-in.&#xD;
&#xD;
          8. Positive result on urine cotinine at screening.&#xD;
&#xD;
          9. Has the following laboratory abnormalities at screening:&#xD;
&#xD;
               1. ALT or AST Grade 2 or greater (&gt; 2.0 times ULN)&#xD;
&#xD;
               2. Creatinine Grade 2 or greater (&gt;1.6 times ULN)&#xD;
&#xD;
               3. Pancreatic lipase Grade 2 or greater (&gt;1.6 times ULN)&#xD;
&#xD;
               4. Amylase Grade 2 or greater (&gt;1.6 times ULN)&#xD;
&#xD;
               5. Total bilirubin Grade 2 or greater&#xD;
&#xD;
               6. CPK (&gt; 1.25 times ULN) If exclusionary lab criteria are met, values may be&#xD;
                  confirmed by repeat evaluation.&#xD;
&#xD;
         10. Has a positive test for hepatitis B surface antigen, hepatitis C antibody, or HIV at&#xD;
             screening.&#xD;
&#xD;
         11. Seated blood pressure (BP) is less than 90/40 mmHg or greater than 140/90 mmHg at&#xD;
             screening, Day -1 (check-in) or predose. Out-of-range vital signs may be repeated once&#xD;
             for confirmation. Out of range values will not be considered AEs if the repeat&#xD;
             assessment is in range.&#xD;
&#xD;
         12. Seated heart rate is lower than 40 beat per minute (bpm) or higher than 99 bpm at&#xD;
             screening, Day -1 (check-in) or predose. Out-of-range vital signs may be repeated once&#xD;
             for confirmation. Out of range values will not be considered AEs if the repeat&#xD;
             assessment is in range.&#xD;
&#xD;
         13. Any clinically significant ECG abnormality at screening (as deemed by decision of the&#xD;
             Investigator and the Sponsor's Medical Monitor).&#xD;
&#xD;
             NOTE: The following may be considered not clinically significant without consulting&#xD;
             the Sponsor's Medical Monitor:&#xD;
&#xD;
               -  Mild first degree A-V block (P-R interval &lt;0.23 sec)&#xD;
&#xD;
               -  Right or left axis deviation&#xD;
&#xD;
               -  Incomplete right bundle branch block&#xD;
&#xD;
               -  Isolated left anterior fascicular block (left anterior hemiblock) in younger&#xD;
                  athletic subjects&#xD;
&#xD;
         14. QTcF interval &gt;450 msec for males or &gt;470 msec for females at screening, Day -1, or&#xD;
             Day 1 (predose), or history of prolonged QT syndrome. For the triplicate ECGs taken at&#xD;
             screening and on Day -1, the average QTcF interval of the 3 ECG recordings will be&#xD;
             used to determine qualification.&#xD;
&#xD;
         15. Family history of long-QT syndrome or sudden death without a preceding diagnosis of a&#xD;
             condition that could be causative of sudden death (such as known coronary artery&#xD;
             disease, congestive heart failure, or terminal cancer).&#xD;
&#xD;
         16. Use of any prescription medication within 14 days prior to dosing.&#xD;
&#xD;
         17. Use of any over-the-counter (OTC) medication, including herbal products and vitamins,&#xD;
             within 7 days prior to dosing, except acetaminophen. Up to 3 grams per day of&#xD;
             acetaminophen is allowed only at occasional use and at the discretion of the&#xD;
             Investigator prior to dosing.&#xD;
&#xD;
         18. Use of any drugs or substances known to be significant inhibitors of cytochrome P450&#xD;
             (CYP) enzymes and/or significant inhibitors or substrates of P-glycoprotein (P-gp)&#xD;
             and/or organic anion transporting polypeptides (OATP) within 14 days prior to the&#xD;
             first dose of study drug.&#xD;
&#xD;
         19. Use of any drugs or substances known to be inducers of CYP enzymes and/or Pgp,&#xD;
             including St. John's Wort, within 30 days prior to the first dose of study drug.&#xD;
&#xD;
         20. Blood donation or significant blood loss within 56 days before the first dose of study&#xD;
             medication until the end-of-study visit.&#xD;
&#xD;
         21. Plasma donation within 7 days before the first dose of study medication until the&#xD;
             end-of-study visit.&#xD;
&#xD;
         22. Has been on a significantly abnormal diet during the 4 weeks preceding the first dose&#xD;
             of study medication.&#xD;
&#xD;
         23. Unwilling to remove any artificial nails (e.g. acrylic, gel) or fingernail polish and&#xD;
             not use such products for the duration of the study.&#xD;
&#xD;
         24. History or presence of allergic or adverse response to Listerine breath strips or&#xD;
             aspartame.&#xD;
&#xD;
         25. If assigned to the fasted/fed cohort, is lactose intolerant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Lombardi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Global Alliance for TB Drug Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Worldwide Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TBAJ-876</keyword>
  <keyword>Diarylquinoline</keyword>
  <keyword>DARQ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

